Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 31;15(1):849.
doi: 10.1007/s12672-024-01675-w.

Sex hormones and immune regulation in ovarian cancer

Rui Zhao #  1 , Wenqin Lian #  2 , Qiong Xu  3
Affiliations
Review

Sex hormones and immune regulation in ovarian cancer

Rui Zhao et al. Discov Oncol. .

Abstract

Ovarian cancer continues to be a major cause of morbidity and mortality in women, with immune regulation playing a critical role in its progression and treatment response. This review explores the interplay between sex hormones, particularly estrogen and progesterone, and immune regulation in ovarian cancer. We delve into the mechanisms by which these hormones influence immune cell function, modulate immune checkpoints, and alter the tumor microenvironment. Key pathways involving estrogen and progesterone receptors are examined, highlighting their impact on tumor growth and immune evasion. The review also discusses the therapeutic implications of these interactions, including the potential for combining hormone-based therapies with immune checkpoint inhibitors. Personalized medicine approaches, leveraging biomarkers for predicting treatment response, are considered essential for optimizing patient outcomes. Finally, we address current research gaps and future directions, emphasizing the need for advanced research technologies and novel therapeutic strategies to improve the treatment of ovarian cancer through a better understanding of hormone-immune interactions.

Keywords: Estrogen; Immune regulation; Ovarian cancer; Progesterone; Sex hormones.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Primary ways estrogen affects the behavior of ovarian cancer cells
Fig. 2
Fig. 2
The effects of endocrine therapies on the estrogen receptor pathway. Endocrine therapies play a pivotal role in the treatment of hormone-sensitive ovarian cancer by targeting the estrogen receptor (ER) pathway. These therapies include aromatase inhibitors, selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs), each of which employs a distinct mechanism to inhibit ER signaling
See this image and copyright information in PMC

References

    1. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. - DOI - PMC - PubMed
    1. Konstantinopoulos PA, Matulonis UA. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023;4(9):1239–57. - DOI - PubMed
    1. Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl_8):61–5. - DOI - PubMed
    1. Barua A, Bahr JM. Ovarian cancer: applications of chickens to humans. Annu Rev Anim Biosci. 2022;10:241–57. - DOI - PubMed
    1. Colombo N, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol. 2019;30(5):672–705. - DOI - PubMed

LinkOut - more resources